Your browser doesn't support javascript.
loading
SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology.
Chukwueke, Ugonma N; Vera, Elizabeth; Acquaye, Alvina; Hervey-Jumper, Shawn L; Odia, Yazmin; Klesse, Laura J; Dunbar, Erin; Sharma, Akanksha; Fonkem, Ekokobe; Thomas, Alissa A; Werbowetski-Ogilvie, Tamra E; Camelo-Piragua, Sandra; Gatson, Na Tosha N; de la Fuente, Macarena I; Armstrong, Terri S; Porter, Alyx B; Jackson, Sadhana.
  • Chukwueke UN; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Vera E; Neuro-Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.
  • Acquaye A; Neuro-Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.
  • Hervey-Jumper SL; Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, Californa, USA.
  • Odia Y; Neuro-Oncology, Miami Cancer Institute (MCI) at Baptist Health South Florida (BHSF), Kendall, Florida, USA.
  • Klesse LJ; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Dunbar E; Brain Tumor Center, Piedmont Atlanta Hospital, Atlanta, Georgia, USA.
  • Sharma A; Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute at John Wayne Cancer Institute, Santa Monica, California, USA.
  • Fonkem E; Neuro-Oncology, Barrow Neurological Institute, Phoenix, Arizona, USA.
  • Thomas AA; Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
  • Werbowetski-Ogilvie TE; Department of Biochemistry and Medical Genetics, Regenerative Medicine Program, University of Manitoba, Winnipeg, Canada, USA.
  • Camelo-Piragua S; Neuropathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Gatson NTN; Neuroscience & Cancer Institutes, Geisinger Health, Danville, Pennsylvania, USA.
  • de la Fuente MI; Neuro-Oncology Division, Department of Neurology/Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
  • Armstrong TS; Neuro-Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.
  • Porter AB; Department of Neurology, Mayo Clinic Cancer Center, Phoenix, Arizona, USA.
  • Jackson S; Surgical Neurology Branch, NINDS, and Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Neuro Oncol ; 23(11): 1845-1858, 2021 11 02.
Article en En | MEDLINE | ID: mdl-34302487
ABSTRACT

BACKGROUND:

Neuro-oncology has grown tremendously since 2010, marked by increasing society membership, specialized clinical expertise, and new journals. Yet, modest improvement in racial/ethnic diversity amongst clinical trial participants, researchers, and clinicians led us to conduct a survey to identify opportunities to enhance diversity and inclusiveness amongst neuro-oncology professionals.

METHODS:

In summer 2020, the Women and Diversity Committee of the Society for Neuro-Oncology (SNO) distributed an anonymous online survey to members and affiliates including the European Association of Neuro-Oncology (EANO), Asian Society for Neuro-Oncology (ASNO), Society for Neuro-Oncology Latin America (SNOLA) and Society for Neuro-Oncology Sub-Saharan Africa (SNOSSA). The survey captured personal and professional characteristics, biases, effective mentorship qualities, career service metrics, and suggested field/society changes. Results were analyzed by geography, profession, age, racial/ethnic, and sexual identity. Standard descriptive statistics characterized the study population.

RESULTS:

The 386 respondents were predominantly female (58%) with a median age range of 40-49 years (31%), White (65%), and SNO members (97%). Most worked in North America (77%) in a research profession (67%). A majority of White respondents reported never experiencing biases (64%), while the majority of non-White respondents reported unconscious biases/microaggressions, followed by a lack of/limited mentorship. Qualitative assessments showcased that personal/professional success metrics were linked to needed improvements in diversity and inclusion efforts within the neuro-oncology field.

CONCLUSIONS:

The prevalence of racial/ethnic biases and poor mentorship rates amongst underrepresented groups in neuro-oncology is high and potentially linked to the limited diverse representation amongst members and affiliates. These findings warrant a swift implementation of equity and inclusion practices within the neuro-oncology field.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Benchmarking / Oncología Médica Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Benchmarking / Oncología Médica Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article